Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 1.1% – Should You Sell?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)’s stock price traded down 1.1% during mid-day trading on Tuesday . The company traded as low as $3.42 and last traded at $3.45. 12,917 shares changed hands during trading, a decline of 83% from the average session volume of 75,676 shares. The stock had previously closed at $3.49.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Kiora Pharmaceuticals in a research note on Thursday, August 22nd.

Kiora Pharmaceuticals Stock Performance

The stock’s fifty day moving average price is $3.56 and its two-hundred day moving average price is $4.41.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its earnings results on Friday, August 9th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.42. The firm had revenue of $0.02 million for the quarter. As a group, research analysts predict that Kiora Pharmaceuticals, Inc. will post 1.17 EPS for the current year.

Institutional Trading of Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC bought a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals accounts for 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th largest position. Stonepine Capital Management LLC owned 6.86% of Kiora Pharmaceuticals as of its most recent SEC filing. 76.97% of the stock is currently owned by institutional investors and hedge funds.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.